Therefore, MASPs may be an alternative biomarker for the disease activity of SLE (except for patients with M-LN), as our data demonstrated that the decrease of serum MASP-1 level was reversed after treatment (Fig. 3, Table 2). The gene discussed is MASP1; the disease is lobular neoplasia.